Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 +/- famitinib in previously treated ES-SCLC
NCT04884009Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of retlirafusp alfa in small cell lung cancer (SCLC), sponsored by Hengrui. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04884009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884009.